Commentary on Anand et al .

The Coronary Drug Project Research Group. Practical aspects of decision making in clinical trials: The Coronary Drug Project as a case study. Control Clin Trials 1981; 1: 363–76.

Heart Special Project Committee. Organization, review, and administration of cooperative studies (Greenberg report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Control Clin Trials 1988; 9: 137–48.

Ellenberg S Fleming T DeMets D . Data Monitoring Committees in Clinical Trials: A Practical Perspective. John Wiley & Sons, Ltd, West Sussex, 2002.

DeMets DL Furberg CD Friedman L . Data Monitoring in Clinical Trials: A Case Studies Approach. Springer Science+Business Media, New York, 2006.

US Food and Drug Administration. Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees. Available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf

Drazen J Wood A . Don’t mess with DSMB. N Eng J Med 2010; 363: 477–8.

Fleming TR Green SJ Harrington DP . Considerations for monitoring and evaluating treatment effects in clinical trials. Control Clin Trials 1984; 5: 55–66.

Anand S Wittes J Yusuf S . What information should a sponsor of a randomized trial receive during its conduct? Clin Trials 2011 (in press).

Lan KKG Wittes J . The B-value: A tool for monitoring data. Biometrics 1988; 44: 579–85.

Borer JS Gordon D Geller N . When should data and safety monitoring committees share interim results with sponsors? J Am Med Assoc 2008; 299: 1710.

CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomized trial. Lancet 2001; 357: 1385.